Compare Bristol-Myers Squibb Co (BMY) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Rent the Runway Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while Rent the Runway Inc trades at $3.48 (market cap $109.66M). The key difference: Bristol-Myers Squibb Co is far larger — about 1060.6× Rent the Runway Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| BMY | RENT | |
|---|---|---|
Market Cap | $116.30B | $109.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $9.39 |
52-Week Low | $42.60 | $3.10 |
Enterprise Value | $152.24B | $269.76M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
RENT trades at $3.34, down 0.3% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear attractive with a P/E of 0.44 and P/S of 0.18, though negative equity of -$182.5 million raises concerns. Leadership transition is underway with the CEO stepping down in May 2026.
The outlook remains challenging despite revenue growth, as profitability and cash flow are negative. Analyst consensus is mixed with 42% buy ratings but significant debt and negative equity pose substantial risks. The stock offers potential upside if new initiatives improve margins, but execution risk is high amid leadership changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
